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A B S T R A C T
Purpose
Multivitamin use is widespread in the United States, especially among patients with cancer.
However, the influence of multivitamin supplementation on cancer recurrence and death after a
curative resection of colon cancer is unknown.
Patients and Methods
We conducted a prospective, observational study of 1,038 patients with stage III colon cancer
enrolled in a randomized adjuvant chemotherapy trial. Patients reported on multivitamin use during
and 6 months after adjuvant chemotherapy. Patients were observed until March 2009 for disease
recurrence and death. To minimize bias by occult recurrence, we excluded patients who recurred
or died within 90 days of their multivitamin assessment.
Results
Among 1,038 patients, 518 (49.9%) reported multivitamin use during adjuvant chemotherapy.
Compared with nonusers, the multivariate hazard ratio (HR) for disease-free survival was
0.94 (95% CI, 0.77 to 1.15) for patients who used multivitamins. Similarly, multivitamin use
during adjuvant chemotherapy was not significantly associated with recurrence-free survival
(multivariate HR, 0.93; 95% CI, 0.75 to 1.15) or overall survival (multivariate HR 0.92;
95% CI, 0.74 to 1.16). Multivitamin use reported 6 months after completion of adjuvant
chemotherapy was also not associated with improved patient outcome, and consistent
use both during and following adjuvant therapy conferred no benefit. Neither an increasing
number of tablets nor increasing duration of use before cancer diagnosis was associated with
cancer recurrence or mortality. Multivitamin use also did not improve the rates of grade 3 and higher
GI toxicity.
Conclusion
Multivitamin use during and after adjuvant chemotherapy was not significantly associated with
improved outcomes in patients with stage III colon cancer.
J Clin Oncol 28:4354-4363. © 2010 by American Society of Clinical Oncology
INTRODUCTION
More than half of the American population cur-
rently uses dietary supplements.1 Among these,
multivitamins comprise the majority of supple-
ments, used by approximately 30% of Americans in
the belief that they will prevent and treat chronic
diseases such as cancer. Although vitamin deficiency
is uncommon in the United States, multivitamin use
is growing, resulting in annual sales of more than
$20 billion. Despite health product claims touting
the benefits of multivitamins, studies examining
their efficacy in decreasing the risk of and mortality
from cancer have been conflicting.
Epidemiologic and laboratory studies indicate
that diet and other lifestyle factors have a significant
influence on colon carcinogenesis. In particular,
preclinical studies have demonstrated the antineo-
plastic properties of folate,2,3 vitamin C,4 vitamin
D,5-7 vitamin E,4 calcium,8 and retinol.9 Administra-
tion of various nutrient mixtures have also resulted
in growth inhibition of colon cancer xenografts10
and prevention of lung tumors in mice.11 However,
an observational study in the Women’s Health Ini-
tiative found that multivitamin use did not reduce
the risk of cancer, including colorectal cancer.12 In
contrast, other epidemiologic studies show a de-
creased risk of colorectal cancer with multivitamin
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supplementation,13 often only after past use14 or many years
of supplementation.15
Beyond primary prevention, the effect of multivitamins on the
outcome of patients with established colon cancer is unknown. In the
United States, 26% to 77% of cancer survivors report multivitamin
use.16 Consequently, it is critical to assess the impact of multivitamins
on treatment and survival. We prospectively examined the influence
of multivitamin use on survival in stage III colon cancer patients
enrolled in a completed National Cancer Institute (NCI) –sponsored
clinical trial of adjuvant chemotherapy.
PATIENTS AND METHODS
Study Population
Patients in this prospective cohort study were participants in the NCI-
sponsored Cancer and Leukemia Group B (CALGB) trial for stage III colon
cancer (89803) that compared adjuvant fluorouracil and leucovorin to irino-
tecan, fluorouracil, and leucovorin.17 From April 1999 to May 2001, 1,264
patients were enrolled. A self-administered questionnaire that captured diet
and lifestyle habits was given to patients midway through their therapy (4
months after surgery; questionnaire 1 [Q1]) and again 6 months after comple-
tion of treatment (14 months after surgery; questionnaire 2 [Q2]). The proto-
col amendment to survey diet and lifestyle was activated after the first 87
patients were enrolled; therefore, only 1,177 patients were eligible for this
companion study (Fig 1).
Patients were eligible for the treatment trial if they had undergone a
complete surgical resection of the primary tumor within 56 days of study entry
and had regional lymph node metastases but no distant metastases. Patients
were required to have a baseline Eastern Cooperative Oncology Group perfor-
mance status of 0 to 2 and adequate bone marrow, renal, and hepatic function.
Median household income was estimated using concurrent census data deter-
mined by the patient’s zip code. All patients signed informed consent, ap-
proved by each institution’s review board.
Multivitamin Assessment
Multivitamin use was assessed both during (Q1) and after completion of
adjuvant chemotherapy (Q2). On Q1, participants were asked, “Have you ever
regularly taken multivitamins?” with an option for “Never have,” “Have in the
past only,” or “Currently taking them.” Those who reported past use were
asked to provide the number of years of use (1 year or shorter, 2 to 4 years, 5 to
9 years, or 10 years or longer). Those who reported current use were asked
about number of multivitamins taken per week (2 or fewer, 3 to 5, 6 to 9, or 10
or more) and years of use. In addition, current users were instructed to write in
the brand of multivitamin consumed. On Q2, participants were asked, “Do
you currently take a multivitamin?” with an option for yes or no. Current users
were then asked to provide the number of multivitamins taken per week and
brand used. We excluded patients who recurred or died within 90 days of their
multivitamin assessment to avoid potential bias related to underlying illness.
Study End Points
The primary end point was disease-free survival (DFS), defined as time
from completion of the questionnaire to tumor recurrence, occurrence of a
new primary colon cancer, or death from any cause. Recurrence-free survival
(RFS) was defined as the time from completion of the questionnaire to tumor
recurrence, death with evidence of recurrence, or occurrence of a new primary
colon tumor; patients who died without known recurrence were censored at
the last documented evaluation. Finally, overall survival was defined as the
time from completion of the questionnaire to death from any cause.
Statistical Analyses
Methods for detection of microsatellite instability (MSI) have been pre-
viously described,18,19 and results for the treatment trial have been reported.17
No significant differences were found between treatment arms, thus data for
patients were combined and analyzed according to categories of multivitamin
use during (Q1) and after adjuvant chemotherapy (Q2). All three end points
were examined using Kaplan-Meier curves20 and the log-rank test.21 Cox
proportional hazards regression was used to determine the simultaneous im-
pact of potential confounders.22 The proportionality of hazards assumption
for the effect of multivitamin use was satisfied by examining it as a time-
dependent covariate in the model. We tested for linear trend by entering the






Cancer recurrence, died, or
removed from protocol prior to Q1
(n = 59)
Cancer recurrence or died within 90
days of completion of Q1
(n = 39)
Cancer recurrence or ineligible for
evaluation prior to Q2
(n = 101)
Cancer recurrence or died within 90
days of completion of Q2
(n = 35)
Did not answer multivitamin question
(n = 18)
Final sample size for
Q1 multivitamin use
(n = 1,038)
Final sample size for
Q2 multivitamin use
(n = 810)Did not answer multivitamin question
(n = 12)
Missing information on covariates
(n = 23)
Eligible, but did not complete Q1
(n=23)
Completed Q1
(n = 1,095; 93%)
Completed Q2 but
not Q1 (n = 3)
Completed Q2
(n = 981; 83%)
Eligible, but did not
complete Q2
(n = 117)
Fig 1. Derivation of cohort size. CALGB,
Cancer and Leukemia Group B; Q1, ques-
tionnaire 1; Q2, questionnaire 2.
Multivitamin Use and Colon Cancer Survival
www.jco.org © 2010 by American Society of Clinical Oncology 4355




Multivitamin Use After Completion of
Adjuvant Chemotherapy (Q2)
No (n  520) Yes (n  518) P a No (n  394) Yes (n  416) P a
Median age, years 60.0 61.0 .43b 60.0 60.0 .90b
Range 26-83 21-85 29-81 21-85
Sex, % .004 .006
Male 60 52 61 52
Female 40 48 39 48
Race or ethnicity, % .19 .13
White 87 90 88 92
African American 8 6 7 5
Other 5 4 5 3
Median household income,c $ 40,647 41,347 .16b 39,840 42,449 .001b
Range 17,963-122,956 18,496-117,487 17,963-122,956 20,510-117,487
Family history of colorectal cancer, % .49 .28
Yes 19 17 21 18
No 81 83 79 82
Baseline ECOG performance status,d % .16 .79
0 73 77 76 76
1-2 27 23 24 24
Invasion through bowel wall (T stage),e % .05 .08
T1 and T2 12 16 13 17
T3 and T4 88 84 87 83
No. of positive lymph nodes (N stage), % .19 .10
1-3 (N1) 62 66 64 70
4 (N2) 38 34 36 30
Grade of differentiation, % .90 .24
Well differentiated 6 6 7 5
Moderately differentiated 71 71 73 71
Poorly differentiated or undifferentiated 23 23 20 24
Lymphovascular invasion, % .36 .52
Yes 27 30 27 29
No 73 70 73 71
Perineural invasion, % .47 .61
Yes 8 7 6 6
No 92 93 94 94
Clinical bowel perforation, % .95 .35
Yes 5 5 3 4
No 95 95 97 96
Clinical bowel obstruction, % .66 .35
Yes 23 22 23 20
No 77 78 77 80
Postoperative CEA,f ng/mL, % .82 .74
 5 92 93 95 95
 5 8 7 5 5
Adjuvant chemotherapy arm, % .58 .53
FU/LV 52 50 51 49
IFL 48 50 49 51
Median body mass indexg, kg/m2 27.5 27.2 .11b 28.8 28.0 .02b
Range 15.7-51.8 17.4-45.0 16.8-54.5 17.6-50.2
Median physical activity, MET-hr/wk 4.1 5.4 .009b 6.9 8.3 .13b
Range 0-147.4 0-125.2 0-92.4 0-168.7
Regular aspirin use,h % .02 .37
Yes 12 17 9 11
No 88 83 91 89
Western dietary pattern, median scorei 0.063 0.295  .001b 0.082 0.241 .01
Range 2.441-6.412 1.792-3.565 1.727-3.884 2.44-6.412
Dietary and supplemental intake, median
Vitamin A, U 7,946 14,121  .001b 7,034 13,348  .001b
Range 1,088-72,028 3363-64,526 869-117,858 2,371-79,030
(continued on following page)
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median value of each category of multivitamin use as a continuous variable in
the model.23 Tests of interaction between multivitamin use and potentially
modifying covariates were assessed by entering the cross product of multivita-
min use and the covariate of interest. Adverse events were graded according to
the National Cancer Institute Common Toxicity Criteria version 2.0, and
logistic regression performed to examine the impact of multivitamins on grade
3 and higher toxicity.
Statistical significance was considered at the .05 level, and all P values
were two sided. The sample size for the cohort was determined by the chem-
otherapy treatment trial, which had 82% power to detect hazard ratios (HR) of
0.77 (protective) or 1.3 (detrimental) for overall survival based on an estimated
356 deaths among 1,260 patients. In a posthoc calculation of power based on
the known sample size and number of DFS events for this analysis, we had 80%
power to detect HRs of 0.67 or 1.50.
Patient registration and clinical data collection were conducted by the
CALGB Statistical Center, and analyses performed in conjunction with
CALGB statisticians based on the database frozen on March 31, 2009. Using
Clark’s C,24 the completeness of follow-up for this study was 84.2%; applying
Wu’s modification to adjust for unreported deaths,25 a more realistic assess-
ment was 85.9%.
RESULTS
Baseline Characteristics According to
Multivitamin Use
Baseline characteristics for the patients for whom data on multi-
vitamin use were captured are presented in Table 1. Among 1,038
patients who completed Q1 shortly after initiation of adjuvant chemo-
therapy, 518 (49.9%) reported multivitamin use. Among 810 patients
who remained cancer free and completed Q2 administered 6 months
after completion of therapy, 416 (51.4%) used multivitamins. Patients
who reported multivitamin use were more likely to be female, had
higher household income, had tumors with less extension through the
bowel wall, had lower body mass index (BMI), were more physically
active, were less likely to consume a Western pattern diet, and were
more likely to report regular aspirin use and higher intake of individ-
ual vitamins. Other potentially prognostic patient and tumor charac-
teristics did not differ significantly.
Impact of Multivitamin Use on Cancer Recurrence
and Death
After a median follow-up of 7.3 years (10th and 90th percentiles:
4.4 and 8.1 years, respectively) among the 1,038 patients who com-
pleted Q1 shortly after initiation of adjuvant therapy, 351 patients
recurred and 314 died. Among the 810 patients who completed Q2 6
months after completion of chemotherapy, after a median follow-up
of 6.5 years (10th and 90th percentiles: 4.0 and 7.3 years), 190 recurred
and 169 died. Compared to nonusers, multivitamin users during
adjuvant chemotherapy did not experience a statistically significant
difference in DFS, RFS, or overall survival (Fig 2). Multivitamin use
after adjuvant therapy was also not associated with improved out-
comes. The results remained largely unchanged after adjusting for




Multivitamin Use After Completion of
Adjuvant Chemotherapy (Q2)
No (n  520) Yes (n  518) P a No (n  394) Yes (n  416) P a
Vitamin B6, mg 2.2 4.5  .001b 1.9 4.5  .001b
Range 0.8-154.0 0.9-340.1 0.5-171.2 0.8-325
Vitamin B12, mcg 6.0 13.5  .001b 5.5 13.4  .001b
Range 0.9-65.2 3.5-2,294.0 1.5-51.5 1.2-2,033
Folate, g 388 817  .001b 349 765  .001b
Range 133-1,124 256-4,137 100-998 204-3,041
Vitamin C, mg 136 249  .001b 109 225  .001b
Range 23-1,643 45-11,977 7-1,200 64-8,609
Vitamin D, U 166 586  .001b 151 562  .001b
Range 26-929 84-1,979 25-834 45-1,692
Vitamin E, mg 7.3 26.1  .001b 6.7 27.8  .001b
Range 2.8-500.4 4.6-1,359.3 2.4-577.7 4.4-1,084.6
Calcium, mg 755 955  .001b 670 990  .001b
Range 239-2,599 297-3,418 290-3,003 325-3,339
Retinol, U 1,759 5,618  .001b 1,598 4,874  .001b
Range 278-22,299 784-35,548 103-19,260 177-44,054
Abbreviations: Q1, questionnaire 1; Q2, questionnaire 2; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; FU/LV, fluorouracil/
leucovorin; IFL, bolus fluorouracil, leucovorin, and irinotecan; MET, metabolic equivalent tasks; hr, hour.
aP value calculated using 2 test unless otherwise noted.
bP value calculated using Kruskal-Wallis test.
cBased on 1999 census data as determined by patient zip code.
dA performance status of 0 indicates a patient was fully active; 1, restricted in physically strenuous activity but ambulatory and able to carry out light work; 2,
ambulatory and capable of all self-care but unable to carry out any work activities and up and about more than 50% of waking hours. Performance status was based
on patient status at initiation of chemotherapy (entry into treatment trial).
eT1 or T2 indicates level of invasion was through the bowel wall but not beyond the muscle layer; T3 or T4, level of invasion was through the bowel wall beyond
the muscle layer.
fPostoperative CEA was based on patient status at initiation of chemotherapy (entry into treatment trial).
gBody mass index is calculated as weight in kilograms divided by height in meters squared. Body mass index was based on patient status at initiation of
chemotherapy (entry into treatment trial).
hRegular aspirin use is defined as three or more 325 mg tablets per week.
iHigher scores are indicative of higher intake.
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other predictors of cancer recurrence (Table 2). Compared to patients
who did not use multivitamins during adjuvant chemotherapy, those
who did had a multivariate HR for cancer recurrence or death of 0.94
(95% CI, 0.77 to 1.15). Similarly, multivitamin use after completion of
adjuvant therapy did not significantly improve DFS (adjusted HR,
1.08; 95% CI, 0.83 to 1.41). We assessed the influence of socioeco-
nomic status using concurrent census data on household income as
determined by the patient’s zip code, and found that it did not con-
found the relationship between multivitamin use and patient out-
come. Household income also did not change the final adjusted HRs
for DFS, RFS, and overall survival when added to our model.
We investigated whether there was a dose effect. Based on data
reported during adjuvant therapy (Q1), we did not find a significant
association between an increasing number of multivitamins con-
sumed per week and patient outcome (P trend  .90 for DFS, .96 for
RFS, and .93 for overall survival). There was also no improvement in
DFS, RFS, or overall survival with increasing multivitamin tablets
consumed after completion of chemotherapy (Q2). Similarly, we did
not observe a significant relationship between increasing years of
multivitamin use and patient outcome.
We further examined the influence of consistent multivitamin
use on patient outcome, as defined by use both during and after
adjuvant chemotherapy. Among 799 patients who completed both
questionnaires, 26% never used multivitamins and 40% reported
consistent use. Compared to never-users, patients who reported con-
sistent multivitamin use did not experience a significant DFS, RFS, or
overall survival benefit (Table 3).
Impact of Individual Vitamins on Multivitamin Use
and Cancer Recurrence and Death
We examined selected vitamins that are present in multivitamin
supplements. Addition of total dietary and supplemental intake of
each vitamin individually to the multivariable model did not
change the null relationship between multivitamin use during
adjuvant chemotherapy and DFS (data not shown). Moreover,
total intake of these individual vitamins during adjuvant treatment
was not significantly associated with DFS after adjusting for mul-
tivitamin use and other prognostic factors (P trend  .84 for vitamin
A; .34 for vitamin B6; .49 for vitamin B12; .49 for folate; .71 for vitamin
C; .12 for vitamin D; .63 for vitamin E; .24 for calcium, and .45 for
retinol).Nosignificantinteractionswereseenbetweenanyofthevitamins
and multivitamin use. The same results were seen when we added total
individual vitamin intakes to the multivariate model assessing multi-
vitamin use after completion of adjuvant chemotherapy (Q2).
Impact of Multivitamin Use Across Strata of Other
Predictors of Patient Outcome
We examined the influence of multivitamin use during adjuvant
chemotherapy on DFS across strata of other predictors of cancer
outcome (Fig 3). Although most subgroups did not show a significant
relationship between multivitamins and outcome, a significant inter-
action was observed with age (P  .007). In patients  60 years old,
multivitamin use was associated with a significantly decreased risk of
recurrence and death (adjusted HR, 0.68; 95% CI, 0.51 to 0.91),
whereas no association was seen in patients older than 60. We consid-
ered the possibility that the benefit of multivitamin use among
younger subjects may reflect the greater likelihood of a family history
of colorectal cancer. However, further stratification of patients  60
years old by family history did not reveal significant differences in the
beneficial effect of multivitamin use on DFS (adjusted HR, 0.63; 95%
CI, 0.24 to 1.66 in patients with a family history; adjusted HR, 0.72;
95% CI, 0.53 to 0.99 in those without). In a related analysis, we
explored the association between multivitamins, age, and tumoral
microsatellite instability (MSI). Further adjustment of the multivari-
able model for MSI as determined by both genotyping of microsatel-
lite markers and immunostaining for mismatch repair proteins did
not alter the positive association between multivitamin use and DFS in
patients  60 years of age (P interaction .004 and .006, respectively).
Of note, we did not see a significant interaction between age and
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Fig 2. (A) Disease-free survival, (B) recurrence-free survival, and (C)
overall survival by multivitamin use reported during adjuvant chemotherapy
(questionnaire 1).
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multivitamin use after completion of adjuvant chemotherapy (P in-
teraction  0.11).
BMI may also modify the relationship between multivitamin use
and DFS (P interaction  .05). Obese patients (BMI  30 kg/m2) who
used multivitamins during adjuvant chemotherapy had significantly
improved DFS (adjusted HR, 0.57; 95% CI, 0.39 to 0.82) compared to
those who did not report multivitamin use (Fig 3). In contrast, over-
weight patients (BMI 25 to 29.9 kg/m2) who used multivitamins
experienced an inferior outcome (adjusted HR, 1.52; 95% CI, 1.06 to
2.17), whereas multivitamin use in those with BMI lower than 25
kg/m2 was not significantly associated with DFS (adjusted HR, 0.87;
95% CI, 0.61 to 1.24). Of note, the test for statistical interaction
between BMI and multivitamin use after completion of adjuvant
chemotherapy was not significant (P interaction  .38).
Impact of Multivitamin Use on Toxicity
We explored the influence of multivitamins on the incidence of
the most common grade 3 and higher toxicities.17 There were no
significant differences in the rates of grade 3 and higher leukopenia,
neutropenia, nausea, vomiting, and diarrhea between multivitamin
users and nonusers after adjusting for potential confounding factors
(Table 4). However, multivitamin use was inversely associated with
grade 3 and higher fatigue (adjusted odds ratio [OR], 0.61; 95% CI,
0.39 to 0.94).
DISCUSSION
In this large cohort of patients with stage III colon cancer treated
with surgery and adjuvant chemotherapy, neither multivitamin
use during or after adjuvant therapy was significantly associated
with improved DFS, RFS, or overall survival. Moreover, multivita-
min use did not improve chemotherapy-related gastrointestinal
toxicity, although there was a potential benefit on fatigue. Impor-
tantly, multivitamin use was not found to be detrimental to patient
outcome. To our knowledge, this is the first study to examine the
impact of multivitamin use on survival among patients with estab-
lished colon cancer.
Several observational studies have investigated the association
between multivitamin use and colorectal cancer incidence, with
conflicting results. A case-control analysis using the Surveillance,
Epidemiology, and End Results registry found a 51% reduction in
the risk of colorectal cancer in those who used multivitamins for 10
years (P trend  .001).13 Similarly, in a prospective cohort study
using the Nurses’ Health Study, there was no benefit of multivita-
min use on colorectal cancer until 15 years of use, at which time a
75% reduction in risk was observed (P trend  .001).15 In contrast,
a prospective cohort study using the Women’s Health Study
showed no association between multivitamin use and colorectal
cancer during 10 years of follow-up,26 and participants in the







No Yes No Yes
Cancer recurrence or death from any cause (disease-free survival)
No. at risk 520 518 394 416
No. of events 206 192 109 121
Unadjusted HR Referent 0.89 Referent 1.02
95% CI 0.73-1.09 0.79-1.32
Adjusted HR Referent 0.94 Referent 1.10
95% CI 0.77-1.15 0.84-1.43
Cancer recurrence (recurrence-free survival)
No. at risk 520 518 394 416
No. of events 183 168 92 98
Unadjusted HR Referent 0.88 Referent 0.98
95% CI 0.72-1.09 0.74-1.30
Adjusted HR Referent 0.93 Referent 1.05
95% CI 0.75-1.15 0.78-1.40
Overall mortality (overall survival)
No. at risk 520 518 394 416
No. of events 166 148 83 86
Unadjusted HR Referent 0.86 Referent 0.97
95% CI 0.69-1.07 0.72-1.31
Adjusted HR Referent 0.92 Referent 1.11
95% CI 0.74-1.16 0.82-1.52
Abbreviations: Q1, questionnaire 1; Q2, questionnaire 2; HR, hazard ratio; CEA, carcinoembryonic antigen; FU/LV, fluorouracil/leucovorin; IFL, bolus fluorouracil,
leucovorin, and irinotecan; MET, metabolic equivalent tasks; hr, hour.
Adjusted for age (in years as a continuous variable), sex, family history of colorectal cancer (yes or no), baseline performance status (0 or 1 to 2), depth of invasion
through bowel wall (T1 to T2 or T3 to T4), No. of positive lymph nodes (1 to 3 or 4 or more), grade of tumor differentiation (well differentiated, moderately
differentiated, or poorly differentiated/undifferentiated), presence of bowel obstruction at time of surgery (yes or no), perineural invasion (yes or no), postoperative
CEA ( 5 or  5), treatment arm (FU/LV or IFL), body mass index (in kg/m2 as a continuous variable), physical activity (in MET-hr/week as a continuous variable),
aspirin use ( 3 or  3 tablets per week), and Western pattern diet (as a continuous variable).
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Women’s Health Initiative who used multivitamins did not have a
lower risk of several cancers, including colorectal cancer (HR, 0.99;
95% CI, 0.88 to 1.11).12
Multivitamins consist of several vitamins and micronutrients
that have been purported to influence colorectal carcinogenesis.
Among these, folate is thought to be the micronutrient most likely
responsible for any potential benefit of multivitamins. Folate acts as a
cofactor in single-carbon transfer in nucleic and amino acid metabo-
lism, therefore a deficiency could lead to disturbances in DNA repli-
cation, methylation, and repair.2,3 The amount of folic acid in
multivitamins was increased in 1973 from 100 to 400 g,27 a level
considerably higher than median dietary intake. Numerous epidemi-
ologic studies have demonstrated that higher folate intake is associated
with a lower risk of colorectal adenoma and cancer.28,29 However, a
placebo-controlled trial demonstrated a 67% increase in the risk of
advanced colorectal lesions and a more than two-fold increase in the
risk of developing at least three adenomas with supplemental folic acid
among subjects with prior adenomas.30 Animal studies have suggested
that the timing of folic acid supplementation may be critical; admin-
istration before the existence of neoplastic lesions may prevent tumor
development, whereas administration afterwards may promote tu-
mor progression.31 Of note, in another analysis of stage I to III colo-
rectal cancer patients, higher plasma folate levels were not associated
with inferior survival.32
Higher circulating plasma 25-hydroxyvitamin D3 [25(OH)D]
has been associated with a reduced risk of colorectal cancer,33 and
in a cohort of 304 patients with stage I to IV disease, we observed a
significant reduction in overall mortality with increasing plasma
25(OH)D.34 However, given the limited quantity of vitamin D in
standard multivitamin tablets (200 to 400 U), regular multivitamin
use is unlikely to materially increase 25(OH)D levels.35
In our secondary subset analyses, multivitamin use was asso-
ciated with improved DFS in patients  60 years of age, but not in
those older than 60. Of note, this exploratory finding may simply
reflect chance. Nonetheless, the Nutrition Intervention Trials con-
ducted in Linxian County, China, found that the benefit of beta-
carotene, vitamin E, and selenium in reducing cancer mortality
was greater in participants younger than 55 years of age.36 In
addition, we observed a significant benefit from multivitamin use
among obese patients, who often have greater levels of oxidative
stress.37 It is possible that one or several of the micronutrients
with antioxidant properties in multivitamins is contributing to
improved outcomes in this subgroup of patients. These interac-
tions with younger age and higher BMI require confirmation in
other studies.
There are several advantages to using a cohort within a NCI-
sponsored clinical trial. First, all patients had stage III cancer, reducing
the impact of heterogeneity by disease stage. Second, treatment and
follow-up were standardized, and the date and nature of recurrence
were recorded prospectively. Finally, detailed information on prog-
nostic factors was collected routinely.
Table 3. Impact of Consistent Multivitamin Use on Colon Cancer Recurrence and Mortality
Parameter
Pattern of Multivitamin Use
Never Used Inconsistent Use Consistent Use†
Cancer recurrence or death from any cause (disease-free survival)
No. at risk 210 267 322
No. of events 63 73 92
Unadjusted HR Referent 0.89 0.90
95% CI 0.64-1.25 0.65-1.24
Adjusted HR‡ Referent 0.99 1.02
95% CI 0.70-1.40 0.73-1.41
Cancer recurrence (recurrence-free survival)
No. at risk 210 267 322
No. of events 53 59 76
Unadjusted HR Referent 0.86 0.88
95% CI 0.59-1.25 0.62-1.26
Adjusted HR‡ Referent 0.89 0.96
95% CI 0.61-1.31 0.67-1.38
Overall mortality (overall survival)
No. at risk 210 267 322
No. of events 47 58 63
Unadjusted HR Referent 0.97 0.85
95% CI 0.66-1.43 0.58-1.24
Adjusted HR‡ Referent 1.19 1.07
95% CI 0.80-1.77 0.72-1.57
Abbreviations: HR, hazard ratio; Q1, questionnaire 1; Q2, questionnaire 2; CEA, carcinoembryonic antigen; FU/LV, fluorouracil/leucovorin; IFL, bolus fluorouracil,
leucovorin, and irinotecan; MET, metabolic equivalent tasks; hr, hour.
Inconsistent use includes patients who reported multivitamin use prior to Q1 only, on Q1 only, prior to Q1 and on Q2, and on Q2 only.
†Consistent use includes patients who reported multivitamin use on both Q1 and Q2.
‡Adjusted for age (in years as a continuous variable), sex, family history of colorectal cancer (yes or no), baseline performance status (0 or 1 to 2), depth of invasion
through bowel wall (T1 to T2 or T3 to T4), No. of positive lymph nodes (1 to 3 or 4 or more), grade of tumor differentiation (well differentiated, moderately
differentiated, or poorly differentiated/undifferentiated), presence of bowel obstruction at time of surgery (yes or no), perineural invasion (yes or no), postoperative
CEA ( 5 or  5), treatment arm (FU/LV or IFL), body mass index at time of Q2 (in kg/m2 as a continuous variable), physical activity at time of Q2 (in MET-hr/week
as a continuous variable), aspirin use at time of Q2 ( 3 or  3 tablets per week), and Western pattern diet at time of Q2 (as a continuous variable).
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Several potential limitations deserve comment. Patients who enroll
inrandomizedtrialsmaydifferfromthepopulationatlarge.However,the
prevalence of multivitamin use in our cohort falls within the range re-
ported for patients with cancer overall.16 Moreover, since the study in-
cluded patients from both community and academic centers throughout
North America, our findings should reflect the general population.
Because we relied on self-reported multivitamin use, mis-
classification of the exposure is possible. However, prior studies
have demonstrated such data to be reliable.38 Moreover, multi-
vitamin use was recorded before any knowledge of cancer-
related outcomes, thus reducing the likelihood of reporting
biases. Finally, patients who consume supplements often engage
in other healthful behaviors. In this study, we controlled for
physical activity, BMI, and performance status, among other
factors. However, residual confounding from unknown vari-
ables is possible.
Pinteraction



















  Met-hr/wk ≤ 4.9
Met-hr/wk > 4.9
Multivariate HR (95% CI)











Fig 3. Multivariate hazard ratios (HRs) and 95% CI for cancer recurrence and death (disease-free survival) across strata of various factors, comparing
multivitamin use during adjuvant chemotherapy with no use. ECOG, Eastern Cooperative Oncology Group; PS, performance status; T, depth of invasion
through bowel wall; N1, one to three lymph nodes; N2, four or more lymph nodes; mod diff, moderately differentiated; undiff, undifferentiated;
FU/LV, fluorouracil/leucovorin; IFL, bolus fluorouracil, leucovorin, and irinotecan; BMI, body mass index (kg/m2); Met, metabolic equivalent tasks; hr, hour; wk,
week.
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In conclusion, our large prospective study of patients with stage
III colon cancer found no significant benefit for multivitamin supple-
mentation on patient outcome. These results are consistent with a
conference statement from the National Institutes of Health that con-
cluded there was insufficient evidence to recommend either for or
against the use of multivitamins for chronic disease prevention.1
Nonetheless, further research is needed to assess the utility of individ-
ual vitamins in patients with established colorectal cancer.
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Table 4. Impact of Multivitamin Use During Adjuvant Chemotherapy on the
Incidence of Selected Grade 3 and Higher Toxicities (n  1,034)
Adverse Event




No. at risk 518 516
No. of events 50 45
% 9.7 8.7
Unadjusted OR Referent 0.89
Range 0.59-1.37
Adjusted OR Referent 0.79
Range 0.51-1.23
Neutropenia
No. at risk 518 516
No. of events 117 130
% 22.6 25.2
Unadjusted OR Referent 1.15
Range 0.87-1.54
Adjusted OR Referent 1.19
Range 0.71-1.59
Nausea
No. at risk 518 516
No. of events 69 72
% 13.3 14.0
Unadjusted OR Referent 1.06
Range 0.74-1.51
Adjusted OR Referent 1.00
Range 0.69-1.43
Vomiting
No. at risk 518 516
No. of events 47 59
% 9.1 11.4
Unadjusted OR Referent 1.29
Range 0.86-1.94
Adjusted OR Referent 1.19
Range 0.79-1.80
Diarrhea
No. at risk 518 516
No. of events 162 185
% 31.3 35.9
Unadjusted OR Referent 1.23
Range 0.95-1.59
Adjusted OR Referent 1.19
Range 0.91-1.55
Fatigue
No. at risk 518 516
No. of events 56 38
% 10.8 7.4
Unadjusted OR Referent 0.66
Range 0.43-1.01
Adjusted OR Referent 0.61
Range 0.39-0.94
Any of the above
No. at risk 518 516
No. of events 283 289
% 54.6 56.0
Unadjusted OR Referent 1.06
Range 0.83-1.35
Adjusted OR Referent 0.99
Range 0.76-1.27
(continued in next column)
Table 4. Impact of Multivitamin Use During Adjuvant Chemotherapy on the
Incidence of Selected Grade 3 and Higher Toxicities (n  1,034) (continued)
NOTE. Adverse events were rated according to the National Cancer Institute
Common Toxicity Criteria version 2.0.
Abbreviations: Q1, questionnaire 1; OR, odds ratio; FU/LV, fluorouracil/
leucovorin; IFL, bolus fluorouracil, leucovorin, and irinotecan; MET, metabolic
equivalent tasks; hr, hour.
Adjusted for age (in years as a continuous variable), sex, baseline Eastern
Cooperative Oncology Group performance status (0 or 1 to 2), treatment arm
(FU/LV or IFL), and physical activity at time of Q1 (in MET-hr/week as a
continuous variable).
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